Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCSZ11 Combined With Standard Therapy in Advanced or Metastatic Solid Tumors
NCT07035249Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of DCSZ11 in solid tumor and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
DCSZ11
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07035249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035249.